InflaRx N.V. Overview
Pro stress-test →InflaRx N.V. is a clinical-stage biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, specifically the complement activation factor C5a and its receptor, C5aR. The company has strategically pivoted to prioritize its lead pipeline asset izicopan while managing earlier-stage programs in complement inhibition.
Strategic Profile
Pro stress-test →The company has communicated a strategy to prioritize izicopan as its leading pipeline asset, focusing resources on its development in hidradenitis suppurativa and other inflammation and immunology indications, with reported spending reductions and workforce reduction to extend cash runway. InflaRx maintains dual development tracks with vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for hidradenitis suppurativa and is in Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis.
Competitive Landscape
Pro stress-test →InflaRx competes in the complement-targeting therapeutic space against other clinical and commercial-stage biotech companies. Investors comparing IFRX often look at related companies including Shattuck Labs, Inc., Surrozen Inc, HilleVax, Inc., Macrogenics Inc, and Xbiotech. The company's focus on anti-inflammatory therapeutics targets large unmet medical needs in rare autoimmune and inflammatory skin diseases.
Industry Context
InflaRx N.V. operates in Biopharmaceuticals / Clinical-Stage Drug Development.
Key facts
Founded: 2007 · Headquarters: Jena, Germany · Market cap: $76.6M